Global Cell Lysis & Disruption Market Analysis Report to 2029 - Increasing Acceptance of Advanced Lysis & Disruption Techniques Throughout Downstream Processing Drives Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 28, 2022--
The “Cell Lysis & Disruption Market Analysis by Product, by Technique, by Cell Type, by Application, by End Use, and by Region - Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.
The global cell lysis & disruption market size is estimated to be USD 3,997.0 million in 2021 and is expected to witness a CAGR of 9.76% during the forecast period.
- Merck KGaA (Germany)
- Becton Dickinson and Company (U.S.)
- Miltenyi Biotec B.V. & CO. KG (Germany)
- Danaher Corporation (U.S.)
- Cell Signaling Technology Inc. (U.S.)
- Promega Corporation (U.S.)
- IDEX Corporation (U.S.)
- Bio-Rad Laboratories Inc. (U.S.)
- QIAGEN N.V. (Germany)
- Thermo Fisher Scientific (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
Increasing acceptance of advanced lysis & disruption techniques throughout downstream processing for the production of biologics is a key driver for the growth of the global cell lysis & disruption market.
Additionally, increase in prevalence of chronic diseases, outbreak of the COVID-19 pandemic, government and private funding for research activities, and market expansion by biotechnology companies are some of the other drivers propelling the market growth. However, high cost of process implementation and lack of skilled professionals are expected to restrain the global market growth.
Based on product, the market is segmented into kits & reagents, consumables, instruments, and enzymes. In 2021, the consumables segment accounted for the largest revenue share. This is attributed to the selective product release application coupled with controlled lysis, thereby providing biological uniqueness to the process.
The enzymes segment is expected to grow at the fastest CAGR during the forecast period. This is attributed to the rising availability of varied enzymes for mammalian, bacterial, yeast, and plant samples.
Based on technique, the market is segmented into physical disruption and reagent-based. In 2021, the physical disruption segment accounted for a significant revenue share, however is expected to grow with a decreasing CAGR during the forecast period. This is attributed to the bulky built and high cost of equipment.
Reagent-based segment is anticipated to grow at the fastest CAGR during the forecast period. This is attributed to the fact that they safeguard the native activity of the final biological products that are less harmful and preferably suited for samples in the laboratory.
By Cell Type
Based on cell type, the market is categorized into bacterial cells, mammalian cells, plant cells, and yeast/algae/fungi. In 2021, the mammalian cells method accounted for the largest revenue share and is expected to dominate during the forecast period. This is owing to its extensive usage in biologics manufacturing including vaccines and therapeutic proteins.
This segment is anticipated to grow at a lucrative CAGR during the forecast period, owing to the acceptance of 3D mammalian culture systems in cancer research and stem cell application.
Based on application, the market is categorized into cell organelle isolation, downstream processing, protein isolation, and nucleic acid isolation. The downstream processing and protein isolation segment accounted for the maximum revenue in 2021. The protein isolation segment is expected to grow at a profitable CAGR during the forecast period due to rise in the need for quick and efficient techniques for cell lysis that enable extraction of proteins with minimal oxidation or breakdown.
By End Use
Based on end use, the market is categorized into pharmaceutical & biotechnology companies, academic & research institutes, cell banks, and hospitals & diagnostic labs. The academic & research institutes segment accounted for the highest revenue in 2021.
Rising biotechnology research institutes, especially including molecular and cellular biology courses is a key factor that drives the segment growth. The hospitals and diagnostic labs segment is anticipated to grow at a lucrative CAGR during the forecast period owing to rising drug development projects worldwide.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the heavy government funding and favorable support coupled with the presence of leading biotechnology & biopharmaceutical companies and institutes in this region.
Asia Pacific market is expected to exhibit the fastest CAGR over the forecast period owing to the growing focus of CROs & biopharmaceutical companies in this region to gain higher profitability.
For more information about this report visit https://www.researchandmarkets.com/r/tz4mvf
View source version on businesswire.com:https://www.businesswire.com/news/home/20221228005260/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 12/28/2022 09:25 AM/DISC: 12/28/2022 09:25 AM